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Cerebral amyloid angiopathy (CAA) of amyloid β-protein (Aβ) type is common in Alzheimer’s
disease (AD). Aβ immunotherapies have been reported to induce CAA-related intracere-
bral hemorrhages (ICH) or vasogenic edema. For the purpose of developing a method
to predict CAA-related ICH and other cerebrovascular disorders in AD, the biomarkers,
and risk factors are reviewed. The biomarkers include (1) greater occipital uptake on amy-
loid positron emission tomography imaging and a decrease of cerebrospinal ﬂuid Aβ40
levels as markers suggestive of CAA, and (2) symptomatic lobar ICH, lobar microhem-
orrhages, focal subarachnoidal hemorrhages/superﬁcial siderosis, cortical microinfarcts,
and subacute encephalopathy (caused by CAA-related inﬂammation or angiitis) as imag-
ing ﬁndings of CAA-related ICH and other disorders. The risk factors include (1) old
age and AD, (2) CAA-related gene mutations and apolipoprotein E genotype as genetic
factors, (3) thrombolytic, anti-coagulation, and anti-platelet therapies, hypertension, and
minor head trauma as hemorrhage-inducing factors, and (4) anti-amyloid therapies. Pos-
itive ﬁndings for one or more biomarkers plus one or more risk factors would be asso-
ciated with a signiﬁcant risk of CAA-related ICH and other cerebrovascular disorders.
To establish a method to predict future occurrence of CAA-related ICH and other cere-
brovascular disorders in AD, prospective studies with a large number of AD patients are
necessary, which will allow us to statistically evaluate to what extent each biomarker
or risk factor would increase the risk. In addition, further studies with progress of tech-
nologies are necessary to more precisely detect CAA and CAA-related cerebrovascular
disorders.
Keywords: cerebral amyloid angiopathy,Alzheimer’s disease, intracerebral hemorrhage, cerebrovascular disorders,
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INTRODUCTION
Cerebral amyloid angiopathy (CAA) is cerebrovascular amyloid
deposition, and is classiﬁed into several types according to amyloid
protein involved; among them,sporadicCAAof amyloid β-protein
(Aβ) type is most commonly found in elderly individuals as well as
in patients with Alzheimer’s disease (AD; see review Yamada and
Naiki, 2012).
Cerebral amyloid angiopathy is pathophysiologically related
to both cerebrovascular disorders and dementia as shown in
Figure 1 (Yamada and Naiki, 2012). A subset of patients with
AD spontaneously develop CAA-related intracerebral hemor-
rhages (ICH) and other cerebrovascular events, which may affect
the clinical course of AD; furthermore, in clinical trials for
AD, Aβ immunotherapies induced CAA-related ICH and other
vascular complications (Cordonnier and van der Flier, 2011).
To develop a method to predict CAA-related ICH and other
cerebrovascular events in AD, this article reviews the preva-
lence, clinical manifestations, biomarkers, and risk factors for
CAA and CAA-related cerebrovascular disorders in patients
with AD.
SPECTRUM OF CEREBRAL Aβ AMYLOIDOSIS: CAA WITH OR
WITHOUT AD
High prevalence of CAA in patients with AD as well as of cerebral
parenchymal Aβ deposition (senile plaques, SPs) in patients with
CAA can be explained by the fact that AD and CAA represent two
sides of a single condition, i.e., cerebral Aβ amyloidosis. The length
of Aβ of SPs is mainly 42–43 residues (Aβ42), while that of cere-
brovascular Aβ is mainly 39–40 residues (Aβ40) (Prelli et al., 1988;
Suzuki et al., 1994). Tissue levels of soluble Aβ40 in the brain cor-
relate with severity of CAA (Suzuki et al., 1994). In the process of
vascular Aβ deposition, Aβ42 is initially deposited, and later Aβ40
is massively accumulated (Shinkai et al., 1995). It has been indi-
cated in both human and experimental studies that an increase
of Aβ40 to Aβ42 ratio signiﬁcantly shifts Aβ deposition toward
the cerebral vasculature, resulting in prominent CAA, as demon-
strated in hereditary cerebral hemorrhagewith amyloidosis-Dutch
type (HCHWA-D) with a point mutation at codon 693 of the
Aβ precursor protein (APP) gene that causes a single amino acid
substitution (Glu to Gln) at position 22 of Aβ, and the trans-
genic mouse model of this disease (Herzig et al., 2004). However,
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determinants for the pattern of parenchymal or vascular amyloid
deposition remain to be elucidated for sporadic cases of AD as well
as CAA.
Pathologically, CAA is commonly found in AD, with a preva-
lence of more than 80% (Yamada et al., 1987; Yamada, 2002). The
prevalence and severity of CAA in AD are signiﬁcantly higher
compared with non-AD cases (Yamada, 2002). Actually, some of
patients with AD are complicated with CAA-related cerebrovas-
cular disorders as reviewed in the next section. On the other
hand, a relatively small subset of patients with symptomatic CAA-
related ICHpresent with dementia/AD at onset of ICH, suggesting
vascular-dominant distribution of amyloid deposition in the brain
(Cordonnier et al., 2010; Hirohata et al., 2010).
Thus, the severity of each of vascular and parenchymal amyloid
deposition varies. The wide spectrum of cerebral Aβ amyloidosis
is shown in Figure 2, including “AD with severe CAA,” “severe
CAA without AD,” “AD with no or mild CAA,” and “no AD with
FIGURE 1 | Pathophysiology of cerebral amyloid angiopathy
(CAA)-related disorders. Aβ shows parenchymal or vascular deposition,
depending on dominance of Aβ42 or Aβ40, respectively, in elderly
individuals and patients with Alzheimer’s disease (AD). Cerebrovascular
amyloid deposition, CAA, is related to stroke and dementia.
FIGURE 2 |The spectrum of cerebral Aβ amyloidosis.
no or mild CAA.” Severe CAA with or without AD may be associ-
ated with CAA-related disorders. Figure 3 shows the distribution
of the severity of CAA in elderly individuals [age (mean± SD),
85.9± 8.0 years] with and without AD from our autopsy series
(Yamada, 2002). “No or mild CAA,” that would be clinically free
of CAA-related cerebrovascular disorders, is found in 86% of
non-AD elderly individuals, while in 66% of AD patients, which
would explain that AD patients are associated with higher risk
of CAA-related cerebrovascular disorders than non-AD elderly
subjects.
Patients who initially have the onset of symptomatic CAA-
related ICH without AD may increase parenchymal Aβ deposition
during the clinical course, leading to development of AD (Hiro-
hata et al., 2010). On the other hand, patients who initially have
AD with no or mild CAA may increase vascular Aβ deposition
during the clinical course, which might lead to development of
CAA-related cerebrovascular disorders (Figure 2). The long time
course after onset of AD may allow progression of vascular Aβ
deposition, as observed in the kinetic study of CAA in a transgenic
mouse model (Robbins et al., 2006).
CAA-RELATED INTRACEREBRAL HEMORRHAGE AND OTHER
CEREBROVASCULAR DISORDERS IN AD
INTRACEREBRAL HEMORRHAGE
Symptomatic ICH
Incidence of symptomatic CAA-related ICH in patients with AD
(Figure 4C) has not been elucidated as yet, requiring further
prospective studies. Prevalence of ICH (excluding microhemor-
rhages) among AD cases at autopsy was reported to be 5.6%,
including both CAA-related and non-CAA-related ICH, in a large
autopsy series (Attems et al., 2008); it is suggested that additional
risk is important to develop symptomatic macrohemorrhages,
even if AD patients have CAA or CAA-related microhemorrhages
in the brain.
Microhemorrhages in AD
The frequencies of cerebral microhemorrhages on sensitive mag-
netic imaging (MRI), such as gradient-echo T2*, were reported
FIGURE 3 |The distribution of the severity of CAA in elderly individuals
(n =201; age, 85.9±8.0 years) with and without Alzheimer’s disease
(AD), based on an autopsy series including AD (n =82; age,
86.1±7.9 years) and non-AD cases (n =119; age, 85.7±8.0 years).
Frequencies are shown in the percentages in each of the AD and non-AD
group (The modiﬁed data from the previous report; Yamada, 2002).
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to be 16.7–32%, which are higher than those in general pop-
ulation (5–6%) (Hanyu et al., 2003; Cordonnier et al., 2006,
2007; Nakata-Kudo et al., 2006; Pettersen et al., 2008); micro-
hemorrhages in AD are frequently distributed in lobar distrib-
ution with more numbers compared with those in control sub-
jects (Figure 4A). A recent study with amyloid positron emis-
sion tomography (PET) using 11C-Pittsburgh compound B (PiB)
reported high prevalence of lobar microhemorrhages in PiB-
positive mild cognitive impairment (MCI) and healthy subjects as
well as AD patients, indicating strong association of Aβ deposition
with lobar microhemorrhages (Yates et al., 2011). Microhemor-
rhages were reported to preferentially occur in local regions of
concentrated amyloid indicated by PiB retention (Dierksen et al.,
2010).
CONVEXAL SUBARACHNOID HEMORRHAGE OR SUPERFICIAL
SIDEROSIS
Superﬁcial siderosis associated with CAA is detected on MRI in
AD patients (Figure 4B) and was suggested to be a marker of CAA
in AD (Feldman et al., 2008). It was reported that CAA was a
frequent cause of convexal SAH, a subtype of non-aneurysmal
subarachnoid bleeding, in patients over the age of 60 (Kumar
et al., 2010). Superﬁcial siderosis closely accompanied microhe-
morrhages in lobar locations, suggesting a close link between
superﬁcial siderosis and CAA (Vernooij et al., 2009b). Focal sub-
arachnoid hemorrhages in conjunction with or without lobar
microhemorrhages were reported to present with transient repeti-
tive migraine auras or transient ischemic attack mimics (Izenberg
et al., 2009).
WHITE MATTER LESIONS
Althoughwhitematter lesions or hyperintensities detected byMRI
are found in AD,MCI, and healthy elderly subjects as well as CAA,
CAA-related perfusion impairments result in progressive damage
of white matter and cognitive impairment (Smith et al., 2004;
Chen et al., 2006; Yoshita et al., 2006; Viswanathan et al., 2008).
Patients with CAA-related ICH showed occipital dominant white
matter hyperintensities on MRI, compatible with predilection of
CAA pathology for posterior brain regions (Zhu et al., 2012).
FIGURE 4 | (A) Cerebral microhemorrhages with lobar distribution in a
patient with Alzheimer’s disease (AD) on gradient-echoT2* imaging. (B,C)
A patient with AD had presented with multiple, old focal subarachnoid
hemorrhages (superﬁcial siderosis; arrows) onT2-weighted MRI at the time
of the diagnosis of AD (B). The patient later developed a large intracerebral
hemorrhage in the left frontal lobe as shown on CT (C), probably related to
CAA (by courtesy of Dr. Toshiya Fukui, Showa University).
MICROINFARCTS
Cerebral amyloid angiopathy was revealed to be an important risk
factor formicroinfarcts restricted to thewatershed cortical zones in
AD,suggesting a role of cerebral hypoperfusion in the pathogenesis
of cortical microinfarcts (Suter et al., 2002).
CONTRIBUTION OF CAA TO DEMENTIA IN AD
Patients with AD and severe CAA may have mixed dementia of
AD and CAA-related vascular cognitive impairment, and there
may be occasionally “a vascular variant of AD” in which most
of Aβ plaques are formed around CAA (Yamada et al., 1997a).
CAA had deleterious effects on cognition even after controlling
for age and AD pathology, and CAA was associated with white
matter abnormalities and cognitive impairment (Greenberg et al.,
2004). It was reported that moderate-to-very severe CAA, but not
mild-to-moderate CAA, is associated with lower performance in
speciﬁc cognitive domains, most notably perceptual speed, sepa-
rately from the effect of AD pathology (Arvanitakis et al., 2011).
Multiple microhemorrhages in AD were reported with worse cog-
nitive function and higher abnormalities of cerebrospinal ﬂuid
(CSF) markers (Goos et al., 2009).
CAA-RELATED INFLAMMATION
A subset of patients with CAA present with CAA-associated vas-
cular inﬂammation or angiitis showing subacute encephalopathy
characterized by cognitive symptoms, seizure,headaches, and focal
neurological deﬁcits with white matter lesions on MRI (Eng et al.,
2004; Oh et al., 2004; Scolding et al., 2005; Kinnecom et al.,
2007). In the clinical course all patients with CAA-related inﬂam-
mation presented with subacute cognitive impairment, but not
with AD-like slowly progressive dementia (Kinnecom et al., 2007).
Parenchymal Aβ load in CAA-related angiitis was signiﬁcantly
lower than in AD (Scolding et al., 2005).
CAA-RELATED CEREBROVASCULAR DISORDERS INDUCED BY Aβ
IMMUNOTHERAPIES IN AD
Recent clinical as well as experimental studies with Aβ
immunotherapies for AD have demonstrated that CAA has
important implications for the future of anti-amyloid therapies.
Experimental studies with AD model mice indicated that Aβ
immunotherapies can induce CAA-related cerebral hemorrhage,
although long-term Aβ immunotherapies could decrease CAA
(Pfeifer et al., 2002; Wilcock et al., 2004, 2007; Racke et al., 2005;
Prada et al., 2007; Schroeter et al., 2008).
In clinical trials with Aβ42 immunization for AD (AN1792,
Elan), immunized patients showed signiﬁcantly higher levels of
CAA and cortical microhemorrhages and microvascular lesions
compared with unimmunized AD controls, although the longest
living had virtually complete absence of both plaques and CAA
(Boche et al., 2008). A CAA-related macrohemorrhage was
reported in an AD patient in the phase 2a AN1792 trial (Orgogozo
et al., 2003). The ﬁndings suggest that Aβ immunization results
in solubilization of plaque Aβ42, which ﬂows out of the brain
parenchyma via the perivascular pathway, causing an increase of
CAA and CAA-related hemorrhages. Eventually, this ﬂow also
results in Aβ clearance from the cerebral vasculature.
In theAN1792 trial,6%of patients treatedwith theAN1792 suf-
fered meningoencephalitis (Orgogozo et al., 2003) and there was
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perivascular inﬁltration of lymphocytes around vessels with CAA
(Nicoll et al., 2003). In a phase 2 trial of bapineuzumab, a human-
ized monoclonal anti-Aβ antibody, vasogenic edema occurred in
9.7% of patients, suggesting a vascular permeability change of
CAA-laden vessels (Salloway et al., 2009). Vasogenic edema was
found only in 2 of 2762 patients with AD at baseline of clinical tri-
als for AD; this indicates that naturally occurring vasogenic edema
is a very rare event in untreated patients with AD, though one
case of vasogenic edema was presumably related to CAA-related
angiitis (Carlson et al., 2011).
MARKERS FOR CAA AND CAA-RELATED CEREBROVASCULAR
DISORDERS IN AD
IMAGING MARKERS
CT/MRI
Although cranial CT is available for symptomatic CAA-related
ICH (macrohemorrhages), MRI is useful to detect small hemor-
rhagic lesions (lobar microhemorrhages and focal subarachnoid
hemorrhages), and ischemic lesions (various white matter lesions
and microinfarcts) as discussed above. Sensitive MR imagings,
such as gradient-echo T2* imaging and susceptibility-weighted
images (SWI), are particularly useful to detect microhemorrhagic
lesions (Nandigam et al., 2009). Although subacute, silent cortical,
or subcortical infarctions were recognized on diffusion-weighted
images (DWI) in patients with CAA (Kimberly et al., 2009),
cortical microinfarcts observed in neuropathological studies are
often undetected on MRI because of their limited size (Brundel
et al., 2012). Introduction of ultra-high strength clinical MR scan-
ners with a higher spatial resolution may make their detection
possible.
Amyloid-PET
In amyloid imaging with a PET ligand, PiB, it was reported that
PiB binding was moderately increased in most patients with prob-
able CAA-related ICH and that the occipital uptake was greater in
CAA-related ICHcomparedwithAD(Johnson et al., 2007; Ly et al.,
2010). In an autopsy-conﬁrmed case, PiB–PET could detect CAA
as the dominant source of signal (Bacskai et al., 2007). Microhem-
orrhages are found to be associated with PiB retention (Dierksen
et al., 2010; Yates et al., 2011).
BIOCHEMICAL MARKERS
Cerebrospinal ﬂuid markers are useful for the diagnosis of AD;
the CSF ﬁndings in AD are characterized by a decrease of Aβ42
levels, an increase of the ratio of Aβ40 to Aβ42, and an increase of
total andphosphorylated tau protein.A signiﬁcant decrease of CSF
Aβ40 as well as Aβ42 was reported in patients with probable CAA,
suggesting the trapping of Aβ40 as well as Aβ42 in the cerebral vas-
culature (Verbeek et al., 2009). Plasma Aβ40 levels were reported
to be associated with extent of white matter hyperintensity in AD,
MCI, or CAA (Gurol et al., 2006).
RISK FACTORS FOR CAA AND CAA-RELATED
CEREBROVASCULAR DISORDERS IN AD
In addition to old age and AD, both genetic and non-genetic risk
factors have been reported for CAA and CAA-related cerebrovas-
cular disorders.
GENETIC RISK FACTORS
Besides hereditary cases of AD/CAA-associated with mutations of
the AβPP or presenilin genes (see reviewYamada and Naiki, 2012),
the ApoE gene (ApoE) has been reported to be risk for sporadic
CAA as well as AD; the ε4 allele for CAA itself, and the ε2 allele for
CAA-related ICH (Greenberg et al., 1995; Premkumar et al., 1996;
Nicoll et al., 1997). Carriers of theApoE ε2 or ε4 allele, particularly,
of the ApoE ε2/ε4 genotype were associated with early recurrence
of lobar ICH in patients who survived a lobar ICH (O’Donnell
et al., 2000). The ApoE ε4 allele constituted a risk factor for cap-
illary CAA (CAA-Type 1) (Thal et al., 2002) and CAA-related
inﬂammation (Kinnecom et al., 2007). The presence of CAA in
head injured cases was signiﬁcantly associated with the ApoE ε4
allele, suggesting an interaction between gene and environment in
development of CAA (Leclercq et al., 2005). Another CAA-related
gene reported by more than one research group is transforming
growth factor (TGF)-β1 (TGF-β1) (Hamaguchi et al., 2005; Peila
et al., 2007).
In addition, CAA was reported to be associated with other
gene polymorphisms, including the presenilin 1 (PS1), α1-
antichymotrypsin (ACT), neprilysin, low-density lipoprotein-
receptor related protein (LRP-1), and angiotensin-converting
enzyme (ACE) genes (Yamada et al., 1997b, 1998, 2003; Yamada,
2002, 2004; Christoforidis et al., 2005; Thal et al., 2010;
Domingues-Montanari et al., 2011). A recent study reported that a
CR1 gene polymorphism, reported to increase risk forAD,was also
associated with risk of CAA–ICH as well as CAA (Bifﬁ et al., 2012).
NON-GENETIC RISK FACTORS
Hypertension
Lowering of blood pressure reduced risk of CAA-related ICH, sug-
gesting that high blood pressure could be a factor inducing ICH
in patients with CAA (Arima et al., 2010).
Thrombolytic, anti-coagulation, and anti-platelet therapies
There is increasing evidence that CAA could be a risk factor for
ICH in thrombolytic therapies for acute myocardial infarction,
pulmonary embolism, or ischemic stroke, and for ICH in war-
farin therapies (Rosand et al., 2000; McCarron and Nicoll, 2004).
The use of anti-platelet drugs such as aspirin was related to the
presence of microbleeds, and to strictly lobar microhemorrhages
suggestive of CAA (Vernooij et al., 2009a). In a systematic review
of clinical trials with aspirin in AD, ICH was found in 3.2% of the
aspirin group, while, in 0% of the control group, suggesting that
aspirin use in AD might pose an increased risk of ICH; a possi-
ble explanation for an increased risk of ICH could be CAA in AD
(Thoonsen et al., 2010).
Anti-amyloid therapies
As discussed above, clinical trials with Aβ immunotherapies for
AD could induce CAA-related ICH and microvascular lesions
(Orgogozo et al., 2003; Boche et al., 2008), inﬂammation around
CAA (Nicoll et al., 2003), and vasogenic edema related proba-
bly to vascular permeability changes of CAA-laden vessels (Sal-
loway et al., 2009) These ﬁndings in the Aβ immunotherapies
(Nicoll et al., 2003; Orgogozo et al., 2003; Boche et al., 2008; Sal-
loway et al., 2009) suggest that, generally, anti-amyloid therapies
with the removal effects of parenchymal Aβ may be complicated
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with CAA-related cerebrovascular disorders, because solubilized
parenchymal Aβwould ﬂow via the perivascular pathway and may
deposit on vascular walls resulting in an increase of CAA and
CAA-related cerebrovascular disorders; in addition, in the case
of Aβ immunotherapies, inﬂammatory, or permeability changes
may be also induced in vessels with CAA by immune reactions
with vascular Aβ.
PREDICTING CAA-RELATED INTRACEREBRAL HEMORRHAGE
AND OTHER CEREBROVASCULAR DISORDERS IN AD
Biomarker ﬁndings and risk factors for CAA andCAA-related ICH
and other cerebrovascular disorders are summarized in Table 1.
In the table, CAA-related white matter hyperintensities are not
included as a biomarker, because they are common ﬁndings in
elderly subjects and AD patients with small vessel diseases includ-
ing both CAA and non-CAA. As for CAA-related ICH, the Boston
criteria were proposed for the diagnosis (Knudsen et al., 2001).
When a given person presents with one or more biomarkers plus
one or more risk factors, we need to be careful about future devel-
opment of CAA-related ICH and other cerebrovascular disorders,
and should avoid additional risk factors if they are avoidable
(Table 1).
Alzheimer’s disease is a deﬁnite risk factor for CAA. When
a patient with AD presents with positive ﬁndings for one or
more biomarkers with additional risk factors such as anti-amyloid
therapies, the patient would be associated with higher risk of
CAA-related ICH and other cerebrovascular disorders compared
with AD patients with no positive biomarkers or additional risk
factors. However, the reported data for AD were based on cross-
sectional or retrospective studies; prospective studies of CAA-
related ICH and other cerebrovascular disorders with a large
number of AD patients are necessary to establish a method to
predict them in AD. Such studies will allow us to statistically eval-
uate to what extent each biomarker or risk factor would increase
the risk of future development of CAA-related ICH and other
cerebrovascular disorders in AD patients.
FUTURE DIRECTIONS
In addition to the prospective studies with AD patients, fur-
ther studies with progress of technologies are necessary to more
precisely detect CAA and CAA-related cerebrovascular disorders.
Currently, sensitive MRI, such as gradient-echo T2* and SWI, is
widely used to detect hemorrhages with a characteristic distribu-
tionof CAA for the clinical diagnosis of CAA-relatedhemorrhages.
However,CAAmaynot presentwith hemorrhagic lesions,butwith
other clinical features, such as dementia. Imaging techniques such
as PiB–PET have been used to directly image cerebral amyloid
deposits. However, such PET tracers are unable to distinguish Aβ
from other amyloid proteins, or to distinguish CAA from amyloid
plaques, though the greater uptake in the occipital lobemaybe sug-
gestive of CAA (Bacskai et al., 2007; Johnson et al., 2007; Ly et al.,
2010). More CAA-speciﬁc imaging is required. It was reported
that clinical ﬁeld-strength MRI could directly visualize amyloid
plaques, as demonstrated in animal models (Ronald et al., 2009).
Postmortem detection of Aβ deposition in CAA as well as AD with
7.0 TMRIwas reported (vanRooden et al., 2009). Further progress
in high resolution MRI may enable direct visualization of CAA.
Regarding amyloid-PET, resolution of amyloid deposits on PET
Table 1 | Biomarker findings and risk factors for cerebral amyloid
angiopathy (CAA) and CAA-related intracerebral hemorrhages (ICH)
and other cerebrovascular disorders.
BIOMARKERS
a. Biomarkers suggestive of CAA:
Amyloid imaging with greater occipital uptake
Cerebrospinal ﬂuid markers with a decrease of Aβ40 levels
b. Biomarkers suggestive of CAA-related ICH and other
cerebrovascular disorders:
Symptomatic lobar intracerebral hemorrhages on CT/MRI
Microhemorrhages in lobar cortical–subcortical regions on MRI*
Convexal, non-aneurysmal subarachnoid hemorrhages, or superﬁcial
siderosis on MRI*
Cortical microinfarcts on MRI**
Subacute leukoencephalopathy compatible with CAA-related
inﬂammation or angiitis on MRI
RISK FACTORS
a. General factors:
Old age
Alzheimer’s disease
b. Genetic factors:
CAA-related gene mutations in familial cases***
Apolipoprotein E gene in sporadic cases: ε4 for CAA and ε2 for
hemorrhage
c. Non-genetic factors to induce CAA-related hemorrhages:
Thrombolytic, anti-coagulation, and anti-platelet therapies
Hypertension
Minor head trauma
d. Anti-amyloid therapies
*Gradient-echo T2* or susceptibility-weighted images are recommended to
detect microhemorrhages or focal superﬁcial siderosis.
**Future development of MRI scanners with a higher spatial resolution is neces-
sary to detect cortical microinfarcts.
***Some mutations in the AβPP and presenilin genes are associated with severe
CAA (see a reviewYamada and Naiki, 2012).
imaging would not be enough to distinguish CAA from amyloid
plaques, requiring a new tracer, or technique to identify vascular
amyloid.
As for biochemical markers, we need to establish the values of
plasma aswell asCSFmarkers forCAA.Blood andbrain/CSF levels
of Aβ inﬂuence each other through transport across the blood–
brain barrier, from brain to blood and from blood to brain, using
LRP-1 and receptor for advanced glycation end products (RAGE),
respectively (Bell and Zlokovic, 2009). The integrity of blood ves-
sels is disrupted in CAA (Bell and Zlokovic, 2009). Changes of
plasma as well as CSF levels of Aβ40 and Aβ42 need to be inves-
tigated in a longitudinal study of patients with CAA to further
clarify their value.
Finally, it is required to establish methods for preven-
tion of CAA and CAA-related cerebrovascular disorders.
Some hemorrhage-inducing factors are controllable or avoid-
able, including hypertension and use of thrombolytic/anti-
coagulation/anti-platelet therapies (Rosand et al., 2000; McCar-
ron and Nicoll, 2004; Trouillas and von Kummer, 2006; Vernooij
et al., 2009a; Arima et al., 2010). We need future strategies for
protection of vessel walls against amyloid-related vascular damage
www.frontiersin.org April 2012 | Volume 3 | Article 64 | 5
Yamada Predicting CAA-related intracerebral hemorrhage
such as toxicity of Aβ oligomers, Aβ-induced oxidative stress, and
inﬂammation.
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